Pascal Soriot, the chief executive of Cambridge-headquartered AstraZeneca, has issued a stark warning to Western pharmaceutical companies, urging them to accelerate their pace of innovation to avoid being eclipsed by rapidly advancing Chinese competitors. Speaking to reporters on Monday, Mr Soriot emphasised the need for companies like AstraZeneca to operate at “Chinese speed” to safeguard their future competitiveness and prevent a scenario akin to the Western automotive industry's struggle against dominant Chinese electric vehicle manufacturers.
Mr Soriot highlighted the significant investments being made by Chinese pharmaceutical firms in cutting-edge technologies, such as antibody drug conjugates – which precisely target cancer cells with chemotherapy – and cell therapy, where live cells are introduced to fight diseases. He drew a parallel with the car industry, where Western companies' focus on petrol engines allowed Chinese manufacturers to gain a substantial lead in electric vehicle technology and sales. This strategic shift underscores a potential challenge for the UK and European pharmaceutical sectors if they do not match the speed of innovation from the East.
Despite these external pressures, AstraZeneca, a key FTSE 100 constituent, expressed confidence in achieving its ambitious growth targets. The company reported revenues of £30.7 billion in the first half of 2026, marking a 6% increase from the same period last year at constant exchange rates. AstraZeneca anticipates reaching annual sales of $80 billion (approximately £60 billion) by 2030, a significant jump from last year's $59 billion. This outlook remains positive even following the recent unexpected failure of Wainua, a promising heart disease drug candidate, in its clinical trials earlier this month, which Mr Soriot acknowledged as an inherent risk in biological research.
The CEO also addressed the role of artificial intelligence (AI) in the industry, dismissing concerns about job losses. Instead, he suggested that AI tools would enhance productivity and accelerate drug development, particularly in designing clinical trial protocols, ultimately fostering economic growth within the sector. He noted his personal experience with AI tools making him “faster and smarter”, indicating a positive outlook for technological integration.
Looking ahead, Mr Soriot confirmed plans to engage with the new UK government, led by Andy Burnham, to seek clarity on a contentious deal with the United States. This agreement, reportedly forged under pressure from former US President Donald Trump and his threats of tariffs on UK drug exports, could potentially see the NHS paying billions more for medicines. Analysis has previously suggested the deal could lead to a significant increase in excess deaths in England. Mr Soriot stressed the importance of understanding the new government's priorities regarding healthcare funding and pharmaceutical agreements.